METHOD FOR INDIVIDUAL ASSESSMENT OF SEVERITY OF COMBINED PATHOLOGY IN THERAPEUTIC PATIENTS
	NIKOLAEV YU A; MITROFANOV I M; SEVOSTIANOVA E V; POLIAKOV V I
	2024-03-06
专利权人	SUPERHARD & NEW CARBON MATERIALS INST (SUPE-Non-standard)
申请日期	2024-03-06
专利号	RU2830411-C1
成果简介	NOVELTY - Invention relates to therapy, and can be used to determine the presence of combined pathology—5 and more comorbidities in therapeutic patients. Patient’s sex, body mass index (BMI), blood pressure, low-density lipoprotein (LDL) cholesterol concentrations are determined, high-density lipoprotein (HDL) alpha-cholesterol, blood serum glucose. Concentration of C-reactive protein (CRP) in blood serum is determined, presence of non-alcoholic fatty liver disease (NAFLD), arterial hypertension (AH) is detected in the examined patient. According to the BMI index, the presence of obesity is detected, the LDL cholesterol content is used to detect the presence of low-density lipoprotein hypercholesterolemia (hyper LDL cholesterol), high-density lipoprotein hypocholesterolemia (HDL hypo-cholesterol) is detected by the content of alpha-cholesterol HDL. A calculated coefficient Y is determined for assessing the severity of the combined pathology by formula Y=3.387451+0.3994689*x1+1.240534*x2+0.6011361*x3+0.392105*x4+0.07857636*x5+0.0695682*x6+0.001535169*x7−1.427382*x8, where Y is the design coefficient; x1 is equal to 1 for male patients or 2 for female patients, x2 is equal to 0 in the absence of NAFLD or 1 in the presence of NAFLD, x3 is equal to 0 in the absence of AH or 1 in the presence of AH, x4 is 0 in the absence of obesity or 1 in the presence of obesity, x5 is equal to 0 in the absence of hyper LDL cholesterol or 1 in the presence thereof, x6 is equal to 0 in the absence of hypo HDL cholesterol or 1 in the presence thereof, x7 is the concentration blood serum glucose (mmol/l), x8—concentration of CRP in blood serum (mg/l), *—sign of multiplication. Presence of a combined pathology is determined by formula , where P is an indicator of the presence of a combined pathology; e is Euler's number = 2.7182. If the P value is 0.5 to 1.0, the presence of a combined pathology is determined. If P is from 0.0 to 0.49, the absence of combined pathology is determined. USE - Medicine. ADVANTAGE - Method provides the possibility of detecting at screening examination of patients with risk of high level of combined pathology corresponding to simultaneous presence of 5 and more nosologies, due to formation of group of indicators of patients' health. 1 cl, 8 tbl, 7 ex
IPC 分类号	A61B-005/021 ; A61B-005/107 ; A61B-008/00 ; G01N-033/66 ; G01N-033/68 ; G01N-033/92
国家	俄罗斯
专业领域	生物科学
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/17842
专题	中国科学院新疆生态与地理研究所
作者单位	SUPERHARD & NEW CARBON MATERIALS INST (SUPE-Non-standard)
推荐引用方式 GB/T 7714	NIKOLAEV YU A,MITROFANOV I M,SEVOSTIANOVA E V,et al. METHOD FOR INDIVIDUAL ASSESSMENT OF SEVERITY OF COMBINED PATHOLOGY IN THERAPEUTIC PATIENTS. RU2830411-C1[P]. 2024.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。